Preferred Label : Abaloparatide;
NCIt synonyms : C2.29-methyl(22-L-glutamic Acid(F E),23-L-leucine(F L),25-L-glutamic Acid(H E),26-L-lysine(H
K),28-L-leucine(I L),30-L-lysine(E K),31-L-leucine(I L))Human Parathyroid Hormone-related
Protein-(1-34)-proteinamide; L-Alaninamide, L-alanyl-L-valyl-L-seryl-L-alpha-glutamyl-L-histidyl-L-glutaminyl-L-leucyl-L-leucyl-L-histidyl-L-alpha-aspartyl-L-lysylglycyl-L-lysyl-L-seryl-L-isoleucyl-L-glutaminyl-L-alpha-aspartyl-L-leucyl-L-arginyl-L-arginyl-L-arginyl-L-alpha-glutamyl-L-leucyl-L-leucyl-L-alpha-glutamyl-L-lysyl-L-leucyl-L-leucyl-2-methylalanyl-L-lysyl-L-leucyl-L-histidyl-L-threonyl-;
NCIt definition : A 34 amino acid synthetic analog of human parathyroid hormone-related protein (PTHrP)
(PTHrP(1-34) analog), with bone-growing and bone density conserving activities. Upon
subcutaneous administration, abaloparatide acts similar to PTHrP and targets, binds
to and activates parathyroid hormone 1 (PTH1) receptor (PTH1R), a G protein-coupled
receptor (GPCR) expressed in osteoblasts and bone stromal cells. PTH1R activates the
cyclic AMP (cAMP) signaling pathway and the bone anabolic signaling pathway, leading
to bone growth, increased bone mineral density (BMD) and volume. This correlates with
increased bone mass and strength and prevents or treats osteoporosis and decreases
fractures.;
UNII : AVK0I6HY2U;
CAS number : 247062-33-5;
Drug name : Tymlos;
Molecule name : BIM-44058; BA058;
Origin ID : C158818;
UMLS CUI : C4042342;
Automatic exact mappings (from CISMeF team)
- CISMeF manual mappings
- Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
